The gene editing biotech announced that the European Patent Office has granted the company a patent for its CRISPR/Cas9 genome editing technology.
The company's shares were up 5.5% ahead of the opening bell, hitting $14.49 apiece Tuesday.
This was after the company barely moved on Monday.
Shares were up nearly 2% ahead of market's open, hitting $11.23 apiece. This was after Insys was up 6.5% Monday. Insys focuses on researching the use of cannabis for therapeutics.
Microcap Novavax (NVAX - Get Report) made positive moves ahead of the opening bell Tuesday as well. Shares were up 4.4% ahead of market's opening, hitting 94 cents apiece. The company's focus is vaccines.